日本无码人妻丰满熟妇5g影院,人妻无码一区二区,国产精品一区二区在线播放,精品国产乱码久久久久久蜜柚,亚洲AV无码成人精品

歡迎蒞臨南京沃博生物科技有限公司官方網(wǎng)站!

Erlotinib, Hydrochloride Salt (Tarceva?) 鹽酸埃羅替尼,它賽瓦

貨號(hào) ICG1027 售價(jià)(元) 1315
規(guī)格 100mg CAS號(hào) 183319-69-9
  • 產(chǎn)品簡(jiǎn)介
  • 相關(guān)產(chǎn)品

貨號(hào)

名稱(chēng)

規(guī)格

價(jià)格

ICG1027-0100MG

Erlotinib, Hydrochloride Salt

100MG

1315

ICG1027-0500MG

Erlotinib, Hydrochloride Salt

500MG

2988

產(chǎn)品簡(jiǎn)介:

鹽酸埃羅替尼是表皮生長(zhǎng)因子受體(EGFR/HER-1)酪氨酸激酶的直接作用抑制劑,IC50為2 nM。 表皮生長(zhǎng)因子受體(EGFR)是ErbB家族的一員,該家族包括EGFR (ErbB1)、ErbB2、ErbB3和ErbB4。EGFR的激活依賴于肽生長(zhǎng)因子與受體的結(jié)合。在許多癌癥中,EGFR突變的存在導(dǎo)致EGFP的激活,從而引起細(xì)胞增殖和其他癌癥過(guò)程[1]。

鹽酸埃羅替尼對(duì)EGFR酪氨酸激酶的選擇性抑制導(dǎo)致包括細(xì)胞遷移、增殖、血管生成和凋亡在內(nèi)的癌癥生長(zhǎng)和發(fā)展的中斷。例如,顯示鹽酸埃羅替尼在肝細(xì)胞癌細(xì)胞、Bxpc-3和PANC-1細(xì)胞中誘導(dǎo)細(xì)胞凋亡和G0/G1細(xì)胞周期停滯,從而增強(qiáng)對(duì)細(xì)胞生長(zhǎng)抑制劑的化學(xué)敏感性[2,3]。 此外,該產(chǎn)品被廣泛研究并用于治療人類(lèi)晚期非小細(xì)胞肺癌(NSCLC) [4]。據(jù)報(bào)道,在胰腺癌中,鹽酸埃羅替尼也表現(xiàn)出抗腫瘤作用[5]。

產(chǎn)品性質(zhì):

Cas No.:183319-69-9

別名:鹽酸埃羅替尼; CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride

化學(xué)名:N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride

Canonical SMILES:COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl

分子式:C22H24ClN3O4

分子量:429.91

溶解度:≥ 6.44 mg/mL in DMSO with gentle warming

儲(chǔ)存條件:Store at -20°C

注意事項(xiàng):

為了您的安全和健康,請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。

References:

1.Melosky B. Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. Front Oncol 2014,4:244.

2.Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, et al. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin 2015,36:614-626.

3.Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005,43:661-669.

4.Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol 2014,5:858-864.

5.Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, et al. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer 2014,50:1909-1915.